Injectable Cytotoxic Drugs Market, By Drug Origin (Compounded Cytotoxic Preparations (niche), Generic Cytotoxic Drugs, and Branded Cytotoxic Drugs), By Indication, By End User, By Route of Administration, By Drug Class, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4485
|
Published Date
November 2025
|
Pages
376
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Injectable Cytotoxic Drugs Market size was valued at US$ 19,625 Million in 2024, expanding at a CAGR of 6.50% from 2025 to 2032.
The injectable cytotoxic drugs market encompasses the pharmaceutical sector involved in the development, manufacturing, distribution, and sale of drugs used to treat cancer that are administered via injection. Cytotoxic drugs work by inhibiting cell division, effectively killing cancer cells and preventing their proliferation.
Government support plays a key role in this market. For example, global spending on oncology drugs is rising rapidly: according to the OECD, between 2024 and 2028, global cancerdrug expenditure is projected to grow by 14–17% per year.
Injectable Cytotoxic Drugs Market- Market Dynamics
Increasing Prevalence of Rheumatoid Arthritis Drives Market Growth
The increasing prevalence of rheumatoid arthritis (RA) is expected to drive growth in the injectable cytotoxic drugs market. RA is a chronic autoimmune disorder characterized by persistent joint inflammation, pain, and progressive joint damage. The condition is becoming more widespread due to aging populations, which heighten the risk of genetic mutations and immune system dysfunction that contribute to disease onset. Injectable cytotoxic drugs help manage RA by targeting rapidly dividing cells and suppressing overactive immune responses, thereby slowing disease progression and alleviating symptoms. For example, according to the Australian Institute of Health and Welfare, rheumatoid arthritis accounted for 1,322 deaths in June 2024, equivalent to 5.1 deaths per 100,000 people, representing 0.7% of all deaths in 2022. The disease contributed to 2.0% of the overall disease burden and 16% of the total burden from all musculoskeletal conditions in 2023. Consequently, the rising incidence of rheumatoid arthritis
Injectable Cytotoxic Drugs Market- Segmentation Analysis:
The Global Injectable Cytotoxic Drugs Market is segmented by Drug Origin, Indication, End User, Route of Administration, Drug Class, and Region.
The injectable cytotoxic drugs market can be categorized by drug origin into three main segments:Generic Cytotoxic Drugs, Branded Cytotoxic Drugs, and Compounded Cytotoxic Preparations (niche). Among these, generic cytotoxic drugs are anticipated to see the most significant growth. This expansion is being driven by a rising global cancer burden and increasing pressure on healthcare systems to provide more affordable treatments. Generic injectables offer nearly the same therapeutic efficacy as branded versions but at a substantially lower cost, making them more accessible for both public healthcare providers and patients. Governments and insurers are also actively promoting generics: by encouraging their use, they reduce the long-term cost burden of cancer treatment. For example, generic oncology drugs are projected to grow steadily, with the global generics oncology market estimated to reach USD30,998million by 2034, according to Precedence Research. In many regions, government policies are supporting this shift toward generics to make cancer care more affordable. In India, for instance, the production of generic oncology injectables is particularly high, with the country accounting for 36.1% of the Asia-Pacific sterile oncology generics market in 2024.
On the end-user side, the market is divided into Hospitals, Ambulatory Surgical Centers (ASCs), Cancer & Specialty Clinics, Homecare Settings (including mobile infusion units), and Government Oncology Centers. Of these, hospitals dominate the injectable cytotoxic drugs market. This dominance is because hospital oncology departments have the infrastructure, patient monitoring capacity, and emergency response systems needed to safely administer high-risk chemotherapy infusions. Injectable cytotoxic protocols often demand inpatient settings where trained oncologists, pharmacists, and support staff can manage side effects or complications immediately. Government health systems further strengthen the hospital segment’s leadership. Many national cancer programs and public health schemes prioritize chemotherapy delivery in hospital settings to ensure patient safety, and they reimburse or subsidize such treatments. For instance, as part of India’s healthcare strategy, large public hospitals remain the backbone of cancer care delivery—they are central to implementing government efforts to expand access to affordable injectable chemotherapy using generics.
Injectable Cytotoxic Drugs Market- Geographical Insights
North America dominates the global injectable cytotoxic drugs market, driven by a mature oncology infrastructure that supports broad adoption of advanced treatment modalities such as immunotherapy and radiation. The region’s strong cancer screening programs and early diagnosis efforts increase access to injectable cytotoxic therapies at earlier stages of disease, enhancing outcomes and boosting demand. Moreover, public investment in cancer care is substantial—in OECD countries, cancer increases health system spending by an estimated €PPP449billion annually, raising healthcare expenditure by around 6% compared to a scenario without cancer.
Meanwhile, the Asia-Pacific region is forecasted to grow at the fastest CAGR over the coming years, supported by rising cancer incidence, improvements in healthcare infrastructure, and favorable government oncology policies. Public health programs, partnerships with pharmaceutical companies, and local manufacturing of cancer drugs are driving greater drug accessibility in the region. Additionally, growing government healthcare budgets and expanding health insurance coverage are improving patient access to quality oncology care, which in turn propels market expansion.
Injectable Cytotoxic Drugs Market- Competitive Landscape:
The injectable cytotoxic drugs market is highly competitive, with leading pharmaceutical companies specializing in oncology and chemotherapy vying for market share. Key players include Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb, Fresenius Kabi, and Mylan N.V. (Viatris). These companies are at the forefront of drug development, global distribution, and strategic partnerships aimed at expanding their oncology portfolios. Rising cancer incidence globally, particularly in North America and Asia-Pacific, combined with improved access to injectable therapies, is intensifying competition. Market leaders differentiate themselves through regulatory approvals, the launch of generic products, and scalable manufacturing capabilities, especially within hospital pharmacy networks.
Recent Developments:
- February 2024: Novartis announced a voluntary public takeover offer to acquire MorphoSys AG, a German-based biopharmaceutical company specializing in oncology drugs, for €2.7 billion.
- May 2023: Innovent Biologics Inc. and Eli Lilly and Company jointly received approval from China’s National Medical Products Administration (NMPA) for a supplemental New Drug Application (sNDA) for TYVYT (sintilimab injection). The approval covers its use in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) for patients with non-squamous non-small cell lung cancer.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Johnson and Johnson Services Inc.
- Roche Holding AG
- Sanofi S.A.
- Merck & Co. Inc.
- Bristol-Myers Squibb
- Intas Pharmaceuticals Ltd.
- Natco Pharma
- Zydus Lifesciences Ltd.
- Fresenius Kabi
- Mylan N.V. (Viatris)
- Hikma Pharmaceuticals PLC
- Pfizer Inc.
- Novartis AG (Sandoz - generics)
- Eli Lilly and Company
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Aurobindo Pharma
- Accord Healthcare
- Hospira (a Pfizer company)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals
- Others
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG ORIGIN- MARKET ANALYSIS, 2019 - 2032
- Compounded Cytotoxic Preparations (niche)
- Generic Cytotoxic Drugs
- Branded Cytotoxic Drugs
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Bladder & Prostate Cancer
- Breast Cancer
- Hematological Malignancies
- Ovarian & Cervical Cancer
- Pancreatic & Liver Cancer
- Lung Cancer
- Colorectal Cancer
- Others (Sarcoma, Head & Neck, Gastric)
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Ambulatory Surgical Centers (ASCs)
- Cancer & Specialty Clinics
- Hospitals
- Homecare Settings (with mobile infusion units)
- Government Oncology Centers
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intramuscular (IM)
- Intraperitoneal (used in HIPEC protocols)
- Intrathecal
- Intravenous (IV) Injection/Infusion
- Subcutaneous (for select agents)
- Intraperitoneal (used in HIPEC protocols)
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Plant Alkaloids
- Cytotoxic Antibodies
- Antimetabolites
- Alkylating Drugs
- Others
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Injectable Cytotoxic Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Injectable Cytotoxic Drugs Market Snippet by Drug Origin
2.1.2. Injectable Cytotoxic Drugs Market Snippet by Indication
2.1.3. Injectable Cytotoxic Drugs Market Snippet by End User
2.1.4. Injectable Cytotoxic Drugs Market Snippet by Route of Administration
2.1.5. Injectable Cytotoxic Drugs Market Snippet by Drug Class
2.1.6. Injectable Cytotoxic Drugs Market Snippet by Country
2.1.7. Injectable Cytotoxic Drugs Market Snippet by Region
2.2. Competitive Insights
3. Injectable Cytotoxic Drugs Key Market Trends
3.1. Injectable Cytotoxic Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Injectable Cytotoxic Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Injectable Cytotoxic Drugs Market Opportunities
3.4. Injectable Cytotoxic Drugs Market Future Trends
4. Injectable Cytotoxic Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Injectable Cytotoxic Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Injectable Cytotoxic Drugs Market Landscape
6.1. Injectable Cytotoxic Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Injectable Cytotoxic Drugs Market – By Drug Origin
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Origin, 2024 & 2032 (%)
7.1.1.1. Compounded Cytotoxic Preparations (niche)
7.1.1.2. Generic Cytotoxic Drugs
7.1.1.3. Branded Cytotoxic Drugs
8. Injectable Cytotoxic Drugs Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
8.1.2. Bladder & Prostate Cancer
8.1.3. Breast Cancer
8.1.4. Hematological Malignancies
8.1.5. Ovarian & Cervical Cancer
8.1.6. Pancreatic & Liver Cancer
8.1.7. Lung Cancer
8.1.8. Colorectal Cancer
8.1.9. Others (Sarcoma, Head & Neck, Gastric)
9. Injectable Cytotoxic Drugs Market – By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
9.1.2. Ambulatory Surgical Centers (ASCs)
9.1.3. Cancer & Specialty Clinics
9.1.4. Hospitals
9.1.5. Homecare Settings (with mobile infusion units)
9.1.6. Government Oncology Centers
10. Injectable Cytotoxic Drugs Market – By Route of Administration
10.1. Overview
10.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
10.1.2. Intramuscular (IM)
10.1.3. Intraperitoneal (used in HIPEC protocols)
10.1.4. Intrathecal
10.1.5. Intravenous (IV) Injection/Infusion
10.1.6. Subcutaneous (for select agents)
10.1.7. Intraperitoneal (used in HIPEC protocols)
11. Injectable Cytotoxic Drugs Market – By Drug Class
11.1. Overview
11.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
11.1.2. Plant Alkaloids
11.1.3. Cytotoxic Antibodies
11.1.4. Antimetabolites
11.1.5. Alkylating Drugs
11.1.6. Others
12. Injectable Cytotoxic Drugs Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Injectable Cytotoxic Drugs Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Injectable Cytotoxic Drugs Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Injectable Cytotoxic Drugs Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Injectable Cytotoxic Drugs Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Injectable Cytotoxic Drugs Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Injectable Cytotoxic Drugs Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Johnson and Johnson Services Inc.
13.2.2. Roche Holding AG
13.2.3. Sanofi S.A.
13.2.4. Merck & Co. Inc.
13.2.5. Bristol-Myers Squibb
13.2.6. Intas Pharmaceuticals Ltd.
13.2.7. Natco Pharma
13.2.8. Zydus Lifesciences Ltd.
13.2.9. Fresenius Kabi
13.2.10. Mylan N.V. (Viatris)
13.2.11. Hikma Pharmaceuticals PLC
13.2.12. Pfizer Inc.
13.2.13. Novartis AG (Sandoz - generics)
13.2.14. Eli Lilly and Company
13.2.15. Dr. Reddy’s Laboratories
13.2.16. Sun Pharmaceutical Industries Ltd.
13.2.17. Cipla Ltd.
13.2.18. Aurobindo Pharma
13.2.19. Accord Healthcare
13.2.20. Hospira (a Pfizer company)
13.2.21. Teva Pharmaceutical Industries Ltd.
13.2.22. Amneal Pharmaceuticals
13.2.23. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Johnson and Johnson Services Inc.
- Roche Holding AG
- Sanofi S.A.
- Merck & Co. Inc.
- Bristol-Myers Squibb
- Intas Pharmaceuticals Ltd.
- Natco Pharma
- Zydus Lifesciences Ltd.
- Fresenius Kabi
- Mylan N.V. (Viatris)
- Hikma Pharmaceuticals PLC
- Pfizer Inc.
- Novartis AG (Sandoz - generics)
- Eli Lilly and Company
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Aurobindo Pharma
- Accord Healthcare
- Hospira (a Pfizer company)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals
- Others
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG ORIGIN- MARKET ANALYSIS, 2019 - 2032
- Compounded Cytotoxic Preparations (niche)
- Generic Cytotoxic Drugs
- Branded Cytotoxic Drugs
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Bladder & Prostate Cancer
- Breast Cancer
- Hematological Malignancies
- Ovarian & Cervical Cancer
- Pancreatic & Liver Cancer
- Lung Cancer
- Colorectal Cancer
- Others (Sarcoma, Head & Neck, Gastric)
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Ambulatory Surgical Centers (ASCs)
- Cancer & Specialty Clinics
- Hospitals
- Homecare Settings (with mobile infusion units)
- Government Oncology Centers
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intramuscular (IM)
- Intraperitoneal (used in HIPEC protocols)
- Intrathecal
- Intravenous (IV) Injection/Infusion
- Subcutaneous (for select agents)
- Intraperitoneal (used in HIPEC protocols)
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Plant Alkaloids
- Cytotoxic Antibodies
- Antimetabolites
- Alkylating Drugs
- Others
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
